Reviewer’s report

Title: A Phase II Study of Pulse Dose Imatinib Mesylate and Weekly Paclitaxel in Patients Aged 70 and Over with Advanced Non-Small Cell Lung Cancer

Version: 1 Date: 5 August 2012

Reviewer: Mark McKeage

Reviewer’s report:

This is a well written and interesting paper. Strengths of the clinical trial it reports include its prospective and multicentre design; compelling scientific rationale and strongly supportive preclinical data; that it met its primary endpoint and objective; inclusive of interesting clinical and biological correlative analyses.

Major compulsory revisions
None

Minor essential revisions
None

Discretionary revisions
I recommend that the author’s consider shortening the discussion section, which is long compared to the other sections of the paper. The content of the discussion section could be written more succinctly thereby improving its impact.

Level of interest: An article of importance in its field

Quality of written English: Acceptable

Statistical review: Yes, and I have assessed the statistics in my report.

Declaration of competing interests:

'I declare that I have no competing interests' below.